Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naive patients infected with HCV genotype 1 in Tunisia.

ABSTRACT:

Background

Hepatitis C virus (HCV) non-structural protein 5A (NS5A) inhibitors have been recently developed to inhibit NS5A activities and have been approved for the treatment of HCV infection. However the drawback of these direct acting antivirals (DAAs) is the emergence of resistance mutations. The prevalence of such mutations conferring resistance to HCV-NS5A inhibitors before treatment has not been investigated so far in the Tunisian population. The aim of this study was to detect HCV variants resistant to HCV-NS5A inhibitors in hepatitis C patients infected with HCV genotype 1 before any treatment with NS5A inhibitors.

Methods

Amplification and direct sequencing of the HCV NS5A region was carried out on 112 samples from 149 untreated patients.

Results

In genotype

SUBMITTER: Aissa Larousse J 

PROVIDER: S-EPMC4465297 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature